These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12409969)

  • 1. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
    Cuspidi C; Muiesan ML; Valagussa L; Salvetti M; Di Biagio C; Agabiti-Rosei E; Magnani B; Zanchetti A;
    J Hypertens; 2002 Nov; 20(11):2293-300. PubMed ID: 12409969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
    Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
    Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study.
    Gosse P; Sheridan DJ; Zannad F; Dubourg O; Guéret P; Karpov Y; de Leeuw PW; Palma-Gamiz JL; Pessina A; Motz W; Degaute JP; Chastang C
    J Hypertens; 2000 Oct; 18(10):1465-75. PubMed ID: 11057435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.
    Mitsunami K; Inoue S; Maeda K; Endoh S; Takahashi M; Okada M; Sugihara H; Kinoshita M
    Cardiovasc Drugs Ther; 1998 Oct; 12(5):469-74. PubMed ID: 9926278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.
    Zanchetti A; Omboni S
    Am J Hypertens; 2001 Feb; 14(2):129-34. PubMed ID: 11243303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects.
    Spratt JC; Webb DJ; Shiels A; Williams B
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):227-32. PubMed ID: 11881128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T; Arakawa K
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril.
    Ciulla MM; Paliotti R; Esposito A; Cuspidi C; Muiesan ML; Rosei EA; Magrini F; Zanchetti A
    J Hypertens; 2009 Mar; 27(3):626-32. PubMed ID: 19262230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
    Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE; Jarvis B
    Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
    Asmar R; Lacourcière Y
    J Hypertens; 2000 Nov; 18(11):1683-90. PubMed ID: 11081784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
    Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design.
    Gosse P; Dubourg O; Guéret P; De Simone G; Schmieder R; De Leeuw PW; Degaute JP; García Puig J; Karpov Y; Magometschnigg D; Matos L; Amouyel P; Asmar R; Le Heuzey JY; Nieminen M; Dahlöf B
    J Hum Hypertens; 2002 Sep; 16(9):653-9. PubMed ID: 12214263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.